Sonova Holding AG
SIX:SOON
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
246.2
335.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sonova Holding AG
Sonova Holding AG
Cash
Sonova Holding AG
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sonova Holding AG
SIX:SOON
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Metall Zug AG
SIX:METN
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Medacta Group SA
SIX:MOVE
|
Cash
€20.8m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Straumann Holding AG
SIX:STMN
|
Cash
CHf294.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Medmix Ltd
SIX:MEDX
|
Cash
CHf109m
|
CAGR 3-Years
100%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Sonova Holding AG
Glance View
Sonova Holding AG is a Swiss company that stands at the forefront of the hearing care industry, dedicated to improving the quality of life for individuals with hearing loss. Founded in 1947, Sonova has steadily evolved to become a leader in innovative audiological solutions, encompassing a wide range of hearing aids, cochlear implants, and assistive listening devices. The company operates through well-known brands such as Phonak, Unitron, and Advanced Bionics, catering to a diverse global market. With an unwavering commitment to research and development, Sonova invests significantly in cutting-edge technology and digital solutions, enabling it to set the standard for quality, performance, and sound experience. This innovation not only solidifies its market position but also resonates with its core mission: empowering people to reconnect with their world through better hearing. For investors, Sonova represents a compelling opportunity within a growing industry, driven by demographic trends such as an aging population and increased awareness of hearing health. The company has demonstrated impressive revenue growth and strong profit margins, underpinned by its competitive advantages in R&D and a robust distribution network. In recent years, Sonova has expanded its presence in emerging markets, tapping into new customer bases that present significant long-term growth potential. Additionally, its proactive approach to sustainability and corporate responsibility enhances its appeal, reflecting a commitment to ethical practices and the well-being of the communities it serves. By prioritizing innovation and meeting increasing consumer demand, Sonova is well positioned for continued success, making it an attractive prospect for investors seeking exposure to the healthcare sector.
You don't have any saved screeners yet
